Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Neoplasms, Germ Cell and Embryonal » Neuroectodermal Tumors » Neuroendocrine Tumors » Melanoma
Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Neoplasms, Nerve Tissue » Neuroectodermal Tumors » Neuroendocrine Tumors » Melanoma
Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Nevi and Melanomas » Melanoma
Description
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) MeSH
Hierarchy View
Subtype Terms (3)
Hutchinson's Melanotic Freckle
4 approved drugs
Melanoma, Experimental
5 drugs (3 approved, 2 experimental)
Approved Indicated Drugs (15)
Phase 4 Indicated Drugs (14)
Phase 3 Indicated Drugs (84)
Phase 2 Indicated Drugs (490)
3,4-dihydroxyphenylalaninechrome tautomerase
acetylsalicylic acid (aspirin)
adenoviral vector expressing hsv-tk
allogeneic large multivalent immunogen vaccine
allogeneic natural killer cells
alpha-type-1-polarized dendritic cell
alvac melanoma multi-antigen therapeutic vaccine
anti-gp100:154-162 tcell receptor peripheral blood lymphocyte
anti-gp 100:154 tcell receptor peripheral blood lymphocyte
anti-ny eso-1 t cell receptor cd62l+ cells
anti-ny eso-1 t-cell receptor pbl
anti-p53 t-cell receptor-transduced peripheral blood lymphocytes
Anti-thymocyte Globulin (Rabbit) (Thymoglobulin)
autologous anti-gp 100:154-162 t-cell receptor gene-engineered peripheral blood lymphocytes
autologous anti-gp 100:154-162 t-cell receptor gene-engineered tumor infiltrating lymphocytes
autologous anti-mart-1 f5 t-cell receptor
autologous anti-mart-1 f5 t-cell receptor gene-engineered peripheral blood lymphocytes
autologous anti-mart-1 f5 t-cell receptor gene-engineered tumor infiltrating lymphocytes
autologous dendritic cells electroporated with wt1 mrna
autologous dendritic cells loaded with autologous tumor lysate
autologous dendritic cells loaded with mage-a3, melana and survivin
autologous dexosomes loaded with tumor-specific peptides
autologous melanoma lysate/klh-pulsed autologous dendritic cell vaccine
autologous tumor infiltrating lymphocytes
boronophenylalanine-fructose complex
brentuximab vedotin (adcetris)
bystander-based autologous tumor cell vaccine
d1/3-mage-3-his fusion protein
dec-205/ny-eso-1 fusion protein cdx-1401
dendritic cell-gp100-mart-1 antigen vaccine
dendritic cell-idiotype-keyhole limpet hemocyanin vaccine
dendritic cell-mart-1 peptide vaccine
dendritic cell tumor fusion vaccine
drosophila-peptide pulsed melanoma-reactive autologous cd8+ pbl
hla-a1-binding mage-1/mage-3 multipeptide-pulsed autologous dendritic cell vaccine
hla-a2-binding tyr/mart-1/gp100 multipeptide-pulsed autologous dendritic cell vaccine
human fecal microbiota (Reybota)
human papillomavirus 16 monovalent
hyaluronidase (human recombinant) (hylenex)
in vitro-treated peripheral blood stem cell
lymphokine-activated killer cells
mage-3/melan-a/gp100/na17 pbmc, rhil-12
mart-1, gp100, tyrosinase peptides
mart-1 peptide pulsed dendritic cells
melanoma antigens-specific cd8+ t lymphocytes
melanoma peptide-pulsed dendritic cells
multi-epitope melanoma peptide vaccine
muromonab cd3 (Orthoclone OKT3)
n-(4-hydroxyphenyl)all-trans retinamide
neoantigen-based melanoma vaccine
ny-eso-1 and melan-a/mart-1 peptides
ny-eso-1 reactive tcr retroviral vector transduced autologous pbl
peginterferon beta-1a (Plegridy)
peripheral blood hematopoietic cell
pg13-mage-a3 tcr9w11 transduced autologous peripheral blood lymphocytes
recombinant adenoviral human p53 gene
recombinant fowlpox-tyrosinase vaccine
replication-competent hsv-1 oncolytic virus
telomerase: 540-548 peptide vaccine
tetanus peptide melanoma vaccine
tgfbdnrii-transduced autologous tumor infiltrating lymphocytes
trastuzumab emtansine (kadcyla)
tyrosinase/gp100/mart-1 peptides
Phase 1 Indicated Drugs (373)
allogeneic hematopoietic stem cells (Hemacord)
anti-ny eso-1 tcr-transduced t cells
autologous bulk til 1383i tcr transduced t cells
autologous dendritic cell adenovirus ccl21 vaccine
autologous genetically modified mage a10c796 t cells
autologous genetically modified mage a4c1032 t cells
autologous genetically modified t cells, ny-eso-1c259 t
autologous, lethally irradiated melanoma cells
autologous natural killer cells
autologous til 1383i tcr gene modified t cells
bivalent oral polio vaccine (bopv), type 1 and type 3
canarypox-hil-12 melanoma vaccine
ex vivo-activated autologous lymph node lymphocytes
gvax pancreatic cancer vaccine
hgm-csf herpes simplex virus injection
hsp110-gp100 chaperone complex vaccine
human gp100 plasmid dna vaccine
masct:multiple antigens specific cellular therapy
mem-288 intratumoral injection
modified vaccinia virus ankara vaccine expressing p53
mouse gp100 plasmid dna vaccine
personalized neoantigen vaccine
phentolamine mesylate (regitine)
prostate specific membrane antigen
proteasome sirna and tumor antigen rna-transfected dendritic cells
Other Experimental Indicated Drugs (27)
Organization Involved with Phase 4 Indications (23)
Organization Involved with Phase 3 Indications (117)
Agencia Nacional de Promocion Cientifica y Tecnica, Argentina
Cancer and Leukemia Group B (CALGB)
Centro Oncologico de Excelencia
Chinese Academy of Medical Sciences
DCS Innovative Diagnostik Systeme
Eastern Cooperative Oncology Group
ECOG-ACRIN Cancer Research Group
Elbe Klinikum Buxtehude, Germany
Hiege-Stiftung gegen Hautkrebs
Icahn School of Medicine at Mount Sinai
Innovent Biologics (Suzhou) Co. Ltd.
Italian Network for Tumor Biotherapy
Katholieke Universiteit Leuven
Laboratorio Pablo Cassará S.R.L.
National Cancer Institute (NCI)
National Council of Scientific and Technical Research, Argentina
Oregon Health and Science University
Provectus Biopharmaceuticals, Inc.
Shanghai Junshi Bioscience Co.,Ltd.
St. Luke's University Health Network, Bethlehem, PA
Sunshine Coast University, Australia
Université catholique de Louvain
University of California, Los Angeles
Organization Involved with Phase 2 Indications (380)
A2 Healthcare Taiwan Corporation
Academic and Community Cancer Research United
American Association for Cancer Research
American Society of Clinical Oncology
Assistance Publique - Hôpitaux de Paris
Australia and New Zealand Melanoma Trials Group
BioMed Valley Discoveries, Inc
BioNumerik Pharmaceuticals, Inc.
British Columbia Cancer Agency
California Cancer Assocaties for Research & Excellence
California Institute of Technology
California Pacific Medical Center Research Institute
Cancer Biotherapy Research Group
Cancer Immunotherapy Trials Network
Cancer Treatment Centers of America
Cantonal Hospital of St. Gallen
Case Western Reserve University
Centre Pluridisciplinaire d'Oncologie & LICR, CHUV
Chao Family Comprehensive Cancer Center
Chinese University of Hong Kong
City of Hope National Medical Center
Clinical Research Technology S.r.l.
Comprehensive Cancer Centers of Nevada
Expert Committee for Melanoma of CSCO
Grupo Español Multidisciplinar de Melanoma
Hackensack University Medical Center
Hoag Memorial Hospital Presbyterian
Hoosier Cancer Research Network
Hospital General Universitario Gregorio Marañon
Infinity Pharmaceuticals, Inc.
Instituto de Investigação em Imunologia
Isala Clinics, Zwolle, The Netherlands
Istituto Nazionale per lo Studio e la Cura dei Tumori
James Graham Brown Cancer Center
Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Ludwig Institute for Cancer Research
Manuel Fajardo Clinical Surgical University Hospital
Maria Sklodowska Curie Children's Hospital
Medigen Biotechnology Corporation
Melanoma Research Foundation Breakthrough Consortium
Memorial Sloan-Kettering Cancer Center
Moorgreen Hospital, Southampton
Mt. Sinai Medical Center, Miami
Multidisciplinary Association for Psychedelic Studies
National Cancer Institute, France
National Center for Research Resources (NCRR)
National Comprehensive Cancer Network
Nationales Centrum fur Tumorerkrankungen
National Heart, Lung, and Blood Institute (NHLBI)
National Institute for Health Research, United Kingdom
Netherlands Working Group on Immunotherapy of Oncology
New Mexico Cancer Care Alliance
North Central Cancer Treatment Group
Northern California Melanoma Center
Northern California Melanoma Center, St. Mary's Medical Center
OHARA Pharmaceutical Co., Ltd.
Oncology Service, Wills Eye Institute
Palmetto Hematology Oncology, P.C.
Petrov Research Institute of Oncology
Royal Liverpool & Broadgreen University Hospitals NHS Truts
Royal Marsden Hospital NHS Trust
Russian Academy of Medical Sciences
Saint Francis Memorial Hospital
Saint John's Health Center - John Wayne Cancer Institute (JWCI)
San Diego Pacific Oncology & Hematology Associates
Shenzhen Hank Bioengineering Institute
Simcere Pharmaceutical Co., Ltd
Society of Surgical Oncology (SSO)
State University of New York, Buffalo
Swiss Group for Clinical Cancer Research
Technical University of Dresden
The Christie NHS Foundation Trust
The First People's Hospital of Changzhou
The Jewish General Hospital, Montreal QC, Canada
The University of Texas, Dallas
The University of Texas Health Science Center, Houston
Universidad Complutense de Madrid
Universitaetsklinikum Schleswig-Holstein
Universitair Ziekenhuis Brussel
University of California, Davis
University of California, Irvine
University of California, San Diego
University of California, San Francisco
University of Colorado, Denver
University of Maryland, Baltimore County
University of Medicine and Dentistry of New Jersey
University of Nice Sophia Antipolis
University of North Carolina at Chapel Hill
University of Southern California
University of Texas, San Antonio
University of Western Australia
Vita-Salute University of Milano. Italy
Washington University in St. Louis
Organization Involved with Phase 1 Indications (120)
Centre Hospitalier Universitaire Vaudois
Cooperative Research Centre for Biomedical Imaging Development
Etablissement Français du Sang
Hasumi International Research Foundation
Herbert Irving Comprehensive Cancer Center
Hospital Italiano de Buenos Aires
Ichor Medical Systems Incorporated
Institut National de la Santé Et de la Recherche Médicale, France
Medical University of South Carolina
Molecular Insight Pharmaceuticals
National Center of Competence in Resaerch, Switzerland
National Human Genome Research Institute (NHGRI)
Prologue Research International
Sharp Clinical Oncology Research
Sichuan Huiyang Life Science and Technology Corporation
South Texas Accelerated Research Therapeutics
The John P. Hussman Foundation
Organization Involved with Other Experimental Indications (12)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
